Skip to main content

Table 2 Data related to surgical intervention

From: Taurolidine reduces the tumor stimulating cytokine interleukin-1beta in patients with resectable gastrointestinal cancer: a multicentre prospective randomized trial

 

Taurolidine group

(n = 60)

Control group

(n = 60)

p

Duration of intervention (min)

   

   Colon

206 (74)

191 (53)

0.39

   Stomach

259 (57)

272 (102)

0.57

   Pancreas

318 (58)

371 (163)

0.51

Perioperative mortality rate

2

3

0.5

   Colon

 

1

0.5

   Stomach

2

1

0.5

   Pancreas

 

1

0.5

Perioperative morbidity rate

17

20

0.35

   Colon

8

6

0.54

   Stomach

8

9

0.5

   Pancreas

 

3

0.12

Surgery-related complications

11

13

0.41

Anastomotic leak

6

6

-

Peritonitis

5

3

0.36

Intraperitoneal hemorrhage

1

 

-

Subcutaneous wound infection

5

11

0.08

Non-surgery complications

12

13

0.5

Myocardial infarction

1

2

0.5

Transient cardiac arrhythmia

4

6

0.37

Pneumonia/pleural effusion

9

10

0.5

Acute renal failure

1

3

0.31

Hepatic decompensation

 

1

0.5

  1. Data are mean (SD), median* (range) or number of patients; 30 days mortaility- and complication rate: chi-squared test (Fisher's exact)